Achieve Life Sciences (ACHV) Prices 476.19K Share Common Offering at $10.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
After-Hours Movers 08/03: (YRCW) (SEDG) (VRNS) Higher; (IMUX) (AIHS) (SPCE) Lower (more...)
August 3, 2020 6:14 PM EDTAfter-Hours Stock Movers:
YRC Worldwide (NASDAQ: YRCW) 45% HIGHER; reported Q2 EPS of ($1.09), $0.29 better than the analyst estimate of ($1.38). Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1.01 billion.
SolarEdge Technologies (NASDAQ: SEDG) 12% HIGHER; reported Q2 EPS of $0.70, $0.01 better than the analyst estimate of $0.69. Revenue for the quarter came in at $331.9 million versus the consensus estimate of $319.42 million. SolarEdge Technologies sees Q3 2020 revenue of $325-350 million, versus the consensus of $330.8... More
Achieve Life Sciences (ACHV) Announces Proposed Common Share Offering
August 3, 2020 4:01 PM EDTAchieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its... More
Achieve Life Sciences (ACHV) Announces Patent Granted in U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications
July 31, 2020 8:32 AM EDTAchieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (US 2020/0172544 A1) on novel analogs of... More
